Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT02455895
Other study ID # CM-01-14
Secondary ID
Status Recruiting
Phase N/A
First received May 26, 2015
Last updated May 27, 2015
Start date May 2015
Est. completion date May 2016

Study information

Verified date May 2015
Source NovaBay Pharmaceuticals, Inc.
Contact David W Stroman, Ph.D.
Phone 510-899-8813
Email dstroman@novabay.com
Is FDA regulated No
Health authority United States: Institutional Review Board
Study type Interventional

Clinical Trial Summary

This study is designed to evaluate the effect of Novabay iLid Cleanser, as compared to its Vehicle, on the ocular skin flora.

In the pre-randomization phase, subjects will receive a single application of open-label NovaBay iLid Cleanser.

In the randomization phase of Stages 1 and 2, subjects will self-treat with masked Investigational Product twice daily for ten (10) days.


Description:

This is an adaptive design, randomized, double-masked, vehicle-controlled, multicenter, parallel group study with two treatment arms: NovaBay iLid Cleanser ("Cleanser") and Cleanser Vehicle ("Vehicle").

The study will be conducted in two Stages, each preceded by a pre-randomization phase. Randomization of Cleanser:Vehicle will be 1:1 and 2:1 in Stages 1 and 2 respectively.

In the pre-randomization phase for Stages 1 and 2, subjects who meet all inclusion and no exclusion criteria will be evaluated by clinical examination at a single visit prior to having ocular skin specimens taken before and after treatment with open-label Cleanser.

In the randomization phase for both Stages 1 and 2, subjects who meet all inclusion and no exclusion criteria will be randomized and evaluated at three visits:

- Visit 1: Screening, Day 1

- Visit 2: Day 11 (+2) End of Treatment (EOT)

- Visit 3: Day 18 (±2) Post Treatment Evaluation/Exit Subjects will have ocular skin specimens taken at Visit 1, Day 1. The specimens will be collected before and 20 minutes after the first application of the study Investigational Product performed by study personnel.


Recruitment information / eligibility

Status Recruiting
Enrollment 100
Est. completion date May 2016
Est. primary completion date January 2016
Accepts healthy volunteers No
Gender Both
Age group 6 Years and older
Eligibility Inclusion Criteria:

- Male or female, of any race, at least 6 years of age.

- Must be eligible for a recommendation to use eye lid cleansing/scrubs for:

- Signs of acute or chronic blepharitis, such as eye lid debris (sleeves, collorates, flakes, crusting) requiring eye lid cleansing/scrubs, and/or

- Signs consistent with mild, moderate, or severe meibomian gland disease (MGD) such as dilated and blocked glands with inspissated secretions sluggish or stagnant upon expression.

- Must be able to read, understand and sign an informed consent form that has been approved by an Institutional Review Board/Ethics Committee. If subject is less than 18 years of age, the informed consent must be signed and dated by subject's legally authorized representative (parent or guardian). Assent to participate should also be obtained from subjects under 18 years of age if required by local regulation.

- Must agree to comply with the visit schedule and other requirements of the study. The parent or guardian must agree to ensure compliance of subjects less than 18 years of age.

- Must agree to remove contact lenses, if applicable, for 15 minutes before and after application of the study Investigational Product.

- Must agree for the duration of the study to refrain from use of makeup/cosmetic products used around the eye(s) such as eye liner, mascara, and/or shadow, foundation or powder. Use of such products is allowed if the eyelid skin area is avoided.

Exclusion Criteria:

- Presence of signs and symptoms of bacterial or allergic conjunctivitis or allergic dermatitis at the Day 1 Visit.

- Suspected fungal, viral, Chlamydia or Acanthamoeba infection based on clinical diagnosis.

- Visual acuity not correctable to 1.0 LogMAR or better (equivalent to Snellen 20/200) in either eye using either a Snellen or ETDRS chart.

- Use of any topical ocular medications including tear substitutes during study participation.

- Use of any preserved or non-preserved glaucoma medications during the 14 days prior to Visit 1 and anticipated use during study participation.

- Presence of nasolacrimal duct obstruction.

- Presence of a punctal plug in either eye.

- Any systemic or ocular disease or disorder, complicating factors or structural abnormality that would negatively affect the conduct or outcome of the study.

- Presence of active inflammation and/or active structural change in the cornea, iris or anterior chamber at the Day 1 visit.

- Use of any topical ocular or oral antimicrobial agent within the 3 days prior to Day 1 visit.

- Use of topical ocular corticosteroids or non-steroidal topical ocular anti-inflammatories (NSAIDs), within 3 days prior to study entry and during the trial.

- Use of RESTASIS® (Cyclosporine Ophthalmic Emulsion) 0.05%) in either eye during the trial.

- Any current immunosuppressive disorder (e.g., HIV positive), or use of immunosuppressive therapy (including chemotherapy).

- Participation in any other investigational clinical study within 30 days prior to study enrollment.

- Any subject who is on staff at the investigational site or is a family member of staff personnel.

- Additionally, the Investigator or Medical Monitor may declare any subject ineligible for a sound medical reason.

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Supportive Care


Related Conditions & MeSH terms


Intervention

Device:
iLid Cleanser
Application of iLid Cleanser to reduce bacterial load on the lid and lash margins

Locations

Country Name City State
United States Ophthalmic Research Consultants of Arizona Phoenix Arizona
United States Turner Eye Institute San Leandro California
United States James D. Branch, MD Winston Salem North Carolina

Sponsors (1)

Lead Sponsor Collaborator
NovaBay Pharmaceuticals, Inc.

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Microbiological efficacy Quantitative assessment of numbers of recoverable bacteria before versus after application of test article 20 minutes after application of test article No
Secondary Ocular Signs lid erythema, lid swelling, lid crusting and debris on lashes, bulbar and palpebral conjunctival injection, and meibomian gland secretions (after expression) Assessed on Visit 1(Day 1), Visit 2 (Day 11) and Visit 3 (Day 18) No
See also
  Status Clinical Trial Phase
Completed NCT04475432 - Safety and Efficacy of TP-03 for the Treatment of Demodex Blepharitis Phase 2/Phase 3
Completed NCT05062564 - Efficacy of LipiFlow in Patients Affected by Meibomian Gland Dysfunction in Reducing Post-cataract Surgery Dry Eye N/A
Completed NCT05629390 - Trial to Evaluate the Efficacy and Safety of TP-03, LIBRA Study Phase 3
Terminated NCT02938078 - Ocular Comfort and Inflammation in Lid Hygiene Therapy N/A
Completed NCT01408082 - Efficacy and Safety Study of a Steroid/Antibiotic Combination Eyedrop to Treat Non-Bacterial Blepharitis Phase 3
Completed NCT01028027 - Loteprednol and Tobramycin Versus Tobramycin and Dexamethasone, in the Treatment of Blepharokeratoconjunctivitis Phase 3
Recruiting NCT04858113 - Short-term Effects on Tear Film (Baby Shampoo vs Blephasol) N/A
Completed NCT00560703 - Treatment of Patients With Blepharitis and Facial Rosacea Phase 2
Completed NCT00894530 - The Effects of Azithromycin Ophthalmic Solution, 1% Versus Placebo in Subjects With Blepharitis During a Four-Week Treatment Period (P08638) Phase 2
Completed NCT01115192 - Blephacura Versus Baby Shampoo to Treat Blepharitis N/A
Completed NCT02386774 - Innovative Imaging of the Conjunctiva, Cornea, and Ocular Adnexa N/A
Completed NCT01808560 - Treatment of Meibomian Gland Dysfunction Prior to Cataract Surgery N/A
Completed NCT01089608 - Efficacy and Safety Assessment of Azyter® Eye Drops (T1225) in Patients With Blepharitis Phase 2
Completed NCT00629590 - Safety and Efficacy Pilot Study of AzaSite (Azithromycin) in Subjects With Blepharitis Phase 4
Completed NCT00629941 - Safety and Efficacy Study of AzaSite® in Subjects With Blepharitis Phase 4
Completed NCT03926026 - Study Evaluating the Safety and Tolerability of NCX 4251 for the Treatment of Acute Exacerbations of Blepharitis Phase 2
Recruiting NCT04603222 - Evaluation of SUMMIT BRUSH in Treatment of Blepharitis N/A
Completed NCT02218489 - Safety and Efficacy of KPI-121 in Subjects With Inflammatory Meibomian Gland Disease Phase 2
Completed NCT00796926 - Trial to Compare the Efficacy of Systane Ultra and Refresh Drop in the Treatment of Dry Eye in Asian Eyes Phase 3
Completed NCT00803452 - Lipids of the Human Tear Film and Their Effect on Tear Stability Phase 4